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1. Introduction 
In various myocardial disorders including myocardial ischemia, infarction and subsequent 
cardiac remodelling and heart failure, myocarditis, cardiomyopathy, cardiac allograft 
rejection, chemotherapy induced cardiotoxicity, both necrosis and apoptosis are considered 
to play an important role in the underling pathophysioloy. Molecular and cellular 
dysfunction has been widely investigated in cardiovascular fields using various modalities. 
Of particular, radionuclide imaging technique has advantage for quantitative assessment of 
molecular function in vivo in patients. Especially in patients with coronary artery disease, 
perfusion imaging agents such as 201Tl, 99mTc-MIBI and tetrofosmin with combination of 
stress testing and ECG-gated data acquisition have been used for the simultaneous 
assessment of the ventricular function and severity of myocardial perfusion abnormality 
including its location and size in stress and resting condition. From these data, status of 
myocardial ischemia or jeopardized myocardium, myocardial viability and reversibility of 
wall motion abnormality can be diagnosed to some extent but still insufficiently. Molecular 
imaging may play an important role for assessing the pathophysiology and its severity in 
these various cardiovascular diseases beyond perfusion imaging. This chapter focuses on 
the apoptosis imaging that is one of the most possible nuclear molecular imaging in-vivo at 
this stage, and its clinical application might permit more precise assessment of the 
pathophysiology in various myocardial abnormalities beyond perfusion imaging. 
Four decades ago, the term apoptosis has been introduced by Kerr et. al. as a special form of 
cell death different from necrosis (Kerr, et al., 1972). Necrosis is passive and unregulated 
form of cell death, characterized by irreversible loss of plasma membrane integrity with cell 
swelling and rupture after sudden severe insults which preclude adequate homeostatic 
energy-dependent cell functions, leading to release of intracellular contents and a 
subsequent inflammatory response. Apoptosis on the other hand is characterized 
morphologically by the condensation of nuclear chromatin, cytoplasmic condensation, cell 
shrinkage, followed by the nuclear and cellular fragmentation and phagocytosis of apoptotic 
bodies by neighboring cells in the absence of inflammation. Apoptosis is considered to be an 
active and highly regulated ATP dependent programmed cell daeth process and plays an 
important roles in embryonic developement and maintenace of postnatal tissues and 
contributes to both normal physiology and pathology. Dysregulation of apoptosis results in 
either too littel or too much cell death and implicated in various diseases. For instance, 
insufficient apoptosis may contribute carcinogenesis, on the otherhand, eccessive apoptosis 
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may account for substantial portion of pathogenesis of myocardial infarction and heart 
failure. 
 
 
Fig. 1. Schema of two major pathway for apoptosis. 
Apoptosis can be mediated through the death receptor pathway, or by mitochondrial pathway 
that is initiated by the release of cytochrome c into the cytosol. Both pathways result in 
activation of caspase-3, the final effector enzyme of apoptosis, leading to the cleavage of 
numerous structural and regulatory cellular proteins, thereby producing the apoptotic 
phenotype characterized by cell shrinkage, chromatin condensation, nucleus fragmentation, 
and externalization of phosphatidylserin (PS) on the outside of the cell membrane. 
Apoptosis is mediated by 2 central pathway: the extrinsic (or death receptor) pathway that 
utilizes cell surface receptors (e.g. Fas) and the intrinsic (or mitochondrial) pathway that 
involves the mitochondria and cytoplasmic reticulum (Fig. 1.). The extrinsic or death 
receptor pathway relies on the binding of specific cytokines expressed by other cells, 
including Fas ligand, tumor necrosis factor alfa, or other factors that binds to specific 
cellular receptors. Ligand binding initiates the activation of caspase-8, which in turn 
activates downstream effector caspases including caspase-3, the final effector enzyme of 
apoptosis. In contrast to extrinsic pathway that transduces a specialized set of death stimuli, 
the intrinsic or mitochondrial pathway integrates a broad spectrum of extracellular and 
intracellular stresses such as ischemia, reperfusion injury, chemotherapy, oxidative stress 
etc. These stimuli converges on the mithochondria leading to the release of several factors 
into cytosol including cytochrome c, which activates the initiator caspase-9 via the 
apoptosome followed by the activation of effector caspases. The activation of down stream 
caspases leads to the cleavage of numerous structural and regulatory cellular proteins, 
thereby producing the apoptotic phenotype characterized by cell shrinkage, chromatin 
condensation, nucleus fragmentation, and externalization of phosphatidylserin (PS) on the 
outside of the cell membrane which serves as an “eat me“ signal for phagocyte. Intracellular 
components are packaged by blebbing and the cell is fragmentated into apoptotic bodies 
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and designated to be engulfed and phagocytosed by macrophages and neighbouring cells 
without causing inflammation. 
2. Radipharmaceuticals for molecular imaging of apoptosis 
After the initial description of apoptosis based on the morphological features, several useful 
biochemical and immunohistochemical detection methods were subsequently introduced 
based on the understanding of the basic mechanisms of apoptosis. As a histochemical 
technique for the detection of apoptosis, terminal deoxynucleotidyltransferase-dUTP-nick end-
labeling (TUNEL) assays has become a standard technique for in situ labeling and localization 
of DNA breaks in individual nuclei on tissue section (Gavrieli, et al.,1992). TUNEL is based on 
the specific binding of terminal deoxynucleotidyltransferase (TdT) to 3’-OH ends of 
fragmented DNA. As DNA ladder formation is quite a late feature of apoptosis, TUNEL assay 
appears to be uniquely associated with apoptotic cell death. For the in-vivo imaging initiator 
caspases and effector caspases can be distinguished and serve as potential targets inside the 
apoptotic cells. However, for molecular target for in-vivo imaging, it is favorable that the 
target exists on cell surface rather than in cytoplasm or nucleus. Accordingly, to date, most 
noninvasive imagings of apoptosis target PS on the cell membrane, which is a membrane 
aminophospholipid that is normally located on the inner leaflet of cell membrane but is 
rapidly trnaslocated to the outer leaflet of cell membrane once the cell become apoptotic. 
Annexin V, a 36-kD physiologic protein, binds with nanomolar affinity to PS in a calcium 
dependent manner, therefore, 99mTc labeled annexin V permits imaging of apoptosis in vivo in 
its early stage (Blankenberg, et al., 1998; Hofstra, et al., 2000; Kemerink, et al., 2003). 
2.1 Radiolabeled annexin V 
Annexin V (also known as annexin A5) is consisted of 319 amino acids and a 36-kD 
endogeneous human protein that is mainly distributed intracellularly with very high 
concentrations in placenta, and lower concentrations in endothelial cells, myocardium, skeletal 
muscle, kidneys, skin, red blood cells, platelets, and monocytes. Very low concentrations of 
annexin V (1-6 ng/ml) circulate in blood of healthy humans (Andree et al., 1992). Several 
advantages for the use of annexin V for apoptotic imaging have been described including very 
high affinity for PS with low nanomolar to subnanomolar dissociation constant values, ready 
production by recombinant DNA technology, and lack of toxicity of the protein. 
In healthy cells, anionic phospholipid PS and phosphatidylethanolamine (PE) confined to 
the inner leaflet of the lipid bilayer plasma membrane by an ATP dependent enzyme called 
translocase. On the other hand, ATP dependent enzyme, floppase, pumps cationic 
phospholipids such as phosphatidylcholine (PC) and sphingomyelin to the cell surface. 
Therefore, an asymmetric distribution of different phospholipids between the inner and 
outer leaflet of the plasma membrane is maintained in normal cells. However, at the 
beginning of the execution phase of apoptosis, rapid redistribution of PS and PC across the 
cell membrane is facilitated by a calcium ion-dependent deactivation of translocase and 
floppase and activation of scramblase. Then, PS exposes on the cell surface and annexin V 
become accessible to PS. This PS exposure is attractive target for imaging apoptosis, since it 
is a near universal event in apoptosis, it occurs early after the apoptotic stimulus, and it 
presents millions of binding sites per cell on the cell surface. 
Annexin V and its derivatives have been labeled with 123I, 124I, 125I, 99mTc, 18F, thereby 
providing a broad range of imaging applications in apoptosis research from autoradiography 
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and single photon imaging including SPECT, and to PET. However, most of the 
radiolabeled annexin V used in clinical trials are 99mTc labeled annexin V, because 99mTc is 
characterized by the most suitable radionuclide properties for SPECT imaging in human 
and is inexpensive and easily available. 
99mTc-BTAP-annexin V using a diamide dimercaptide N2S2 chelate for labeling (99mTc- N2S2-
annexin V) was introduced in early 1990s and examined to detect left atrial thrombi in vivo in 
swine (Stratton et al., 1995). Biodistribution and dosimetry study of 99mTc-BTAP-annexin V in 
patients revealed that the radioactivity predominates in kidney, liver and urine bladder and 
fast and extensive bowel excretion of the tracer precludes the assessment of abdominal region 
(Kemerink, et al., 2001a). N2S2 labeling method is cumbersome but radiochemical yield is low 
and had a high degree of non specific tracer excretion into bowel via excretion to bile. 
Accordingly, an improved labeling method using the bifunctional agent 
hydrazinonicotinamide (HYNIC) was introduced (Blankenberg, et al., 1998). 99mTc-labeling 
of reconstituted HYNIC-annexin V can be performed by simply reacting the conjugate with 
99mTc-pertechnetate in the presence of stannous tricine for 5-10min in room temperature and 
it provides 99mTc-HYNIC-annexin V in high radiochemical yield (usually 92-95%) without 
requiring any additional purification step. Phase I clinical trial with 99mTc-HYNIC-annexin V 
also demonstrated strongest uptake in kidney, liver and urine bladder. However, in contrast 
to 99mTc-BTAP-annexin V no bowel excretion was observed in 99mTc-HYNIC-annexin V, 
having a favorable biodistribution for imaging of the abdominal as well as thoracic area.  
As an alternative methods for radiolabeling annexin V, self chelating annexin V mutants 
had been introduced (Tait, et al., 2000, 2005). Annexin V mutants with endogeneous site for 
99mTc chelation such as V-117 and V-128 have major advantages over the HYNIC chelatior in 
terms with lower renal retention. Many other kind of 99mTc-labeled annexin V have been 
introduced, however, only 99mTc-i-annexin V (Kemerink, et al., 2001b) was tested in clinical 
trial in addition to 99mTc-BTAP-annexin V and 99mTc-HYNIC-annexin V.  
As a PET tracer, several approaches to label annexin V with 18F have been developed 
(Grierson, et al. 2004; Murakami et al., 2004).18F-annexin V has lower uptake in the liver, 
spleen, and kidneys than 99mTc-HYNIC-annexin V.  
2.2 Radiolabeled C2A 
C2A domain of synaptotagmin I also binds PS with nanomolar affinity in a calcium-
dependent manner. The C2A is labeled in the form of C2A-GST (GST: glutathione S-
transferase) fusion protein. The fusion protein can be stably labeled with 99mTc at a 
reasonably high radiochemical yield and purity through thiolation using 2-iminothiolane 
(Zhao, et al., 2006). 99mTc-C2A-GST accumulates well in the area at risk in a rat model of 
acute myocardial infarction in both in-vivo imaging and autoradiography. Recently, 18F-
C2A-GST was synthesized and significant uptake in the VX2 rabbit lung cancer with 
paclitaxel induced apoptosis was observed in small animal PET/CT (Wang, et al., 2011). 
Radiochemical purity of 18F-C2A-GST was more than 95% and stable for 4 h after 
formulation. Biodistribution in mice was favorable with major excretion from the kidneys 
and rapid clearance from blood and nonspecific organs. 
2.3 Radiolabeled caspase targeted tracer 
Caspase activation is the central role in the execution of cell death, therefore, caspases are 
the attractive targets for apoptosis imaging. Non-peptide based isatin sulfonamide analogs 
were synthesized with nanomolar potency for inhibiting caspase-3 and caspase-7 and one of 
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the analogs, WC-II-89 was labeled with 18F (Zhou et al., 2006). 18F- WC-II-89 showed a high 
uptake in the liver of chemically induced apoptosis. Although molecules that target caspase-
3 is attractive, there are limited animal data and it is not yet known how sensitive this kind 
of  agents will be for actual imaging in humans. 
2.4 Uncategorized tracer 
Recently a novel family of low molecular mass amphipatic apoptosis markers (ApoSense) 
was developed targeting the cell membrane of apoptotic cells. 18F-labeled 5-fluoropentyl-2-
methyl-malonic acid (18F-ML-10) belongs to this family of low-molecular-weight compounds 
used for the imaging of cell death in vivo. This compound responds to alterations in plasma 
membrane potential and phospholipid scrambling, which are hallmarks of apoptotic cells. 
To which cell membrane targets this probe binds is unknown. After systemic 
administration, the compound can detect apoptotic cells from the early stages of the death 
process, cross the intact plasma membrane, and accumulate in the cytoplasm. In animal 
model of cerebral infarction, selective uptake was observed in the region of ischemia at 24 hr 
after the middle cerebral artery occlusion (Reshef et al., 2008). 
3. Apoptosis imaging in acute myocardial ischemia 
It has been believed that myocardium directly start to die via necrosis shortly after the onset 
of myocardial infarction that march of necrosis spread as a wavefront from endocardium to 
epicardium. However, recent animal experiments with permanent coronary artery occlusion 
revealed that cell death process starts as apoptosis and severe ATP depletion due to 
ischemia may preclude the execution of apoptosis and lead to plasma membrane 
permeability barrier breakdown and secondary necrosis. Therefore, apoptosis imaging 
might play important role in the assessment of myocardial cell death process in acute 
myoacrdial infarction, especially in its early stage. 
3.1 Animal experiment in permanent occlusion of coronary artery 
In a rat model of permanent coronary artery ligation, Kajstura et al. investigated the 
contribution of the apoptosis and necrosis to cardiomyocyte death using TUNEL method 
and DNA laddering for apoptosis and antimyosin monoclonal antibody labeling (Kajstura, 
et a., 1996). After 2 h of the left main coronary artery ligation, TUNEL positive myocytes 
appeared in the central portion of the left ventricular free wall and peaked at 4.5 h. Myosin 
labeled cells also appeared at 2 h after ligation and significantly increased after 6 h to 2 days. 
However, at 2 h after coronary ligation, number of apoptotic cells was 2.8 x 106 and number 
of necrotic cells was 9 x 104. Therefore, early after myocardial infarction, apoptosis is the 
predominant form of cell death, and 1 to 2 days after infarction, necrosis is the dominant 
form of cell death followed by low levels of both apoptosis and necrosis at 7 days after 
infarction. If cells undergoing apoptosis are not cleared before they deplete their 
intracellular ATP stores that are necessary to maintain plasma membrane integrity, plasma 
membrane permeability barrier breakdown occurs and cells are converted from apoptosis to 
necrosis as known as secondary necrosis, results in inflammation. 
3.2 Animal experiment in acute ischemia and reperfusion 
In a mouse model of 15 and 30 min of ischemia and 90 min of reperfusion, percentage of 
cardiomyocytes staining positivity for biotinylated annexin V was far greater than the 
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percentage staining positivity for IgG, which indicates plasma cell membrane leakage 
(Dumont et al., 2000). Accordingly, at least 90 min of reperfusion, most of the annexin V 
uptake might represent PS externalization.  
We investigated the temporal and spatial change of 99mTc-annexin V accumulation in a rat 
model of 20 min coronary artery occlusion and reperfusion. 99mTc-annexin V uptake was 
imaged at 30 min, 90 min, 6 h, 24 h, 3 day, 2 weeks after reperfusion. The strongest 99mTc-
annexin V uptake was observed in the mid myocardium of the area at risk at 30 m and 90 m 
of reperfusion and the uptake expanded to subendocardial and subepicardial layer at 6 h 
after reperfusion, followed by gradual reduction of the uptake over 3 days (Fig. 2) (Taki, et 
al., 2004). On the other hand, TUNEL positivity peaked at 6 h to 1 day after reperfusion. 
These findings are in keeping with the known temporal sequence of apoptosis, in which one 
of the earliest events is externalization of phosphatidylserine, followed by DNA 
fragmentation. Using fluorescent labeled annexin V, real time monitoring of annexin V 
binding to cardiomyocytes after 30 m ischemia and reperfusion demonstrated that 
cardiomyocytes started to bind annexin V within minute and the amount of binding reached 
a maximum within 20-25 m (Dumont, et al., 2001). These finding indicate that apoptosis 
commences just after ischemia and reperfusion and PS externalization reaches plateau 
around 30 m after reperfusion. 
 
 
Fig. 2. Autoradiography of 99mTc-annexin V and 201Tl at various reperfusion time after 20 
min of coronary artery occlusion. 
At a examination time after 20 min ischemia and reperfusion, 99mTc-annexin V (80-150 MBq) 
was injected and 1 h later 201Tl (0.74 MBq) was injected just after the coronary artery 
reocclusion to verify the area at risk. Upper low demonstrated 99mTc-annexin V images and 
lower low shows 201Tl image that represents area at risk. 
The amount of annexin V binding to apoptotic cardiomyocytes after reperfusion depends on 
the severity of ischemia and reperfusion time (Taki, et al., 2007a). In a rat model of 5 min, 10 
min, 15 min ischemia and reperfusion model, degree of 99mTc-annexin V accumulation 
depend on the length of the coronary artery occlusion time and time period after 
reperfusion: significant uptake of 99mTc-annexin V accumulation was observed in 15 min 
and 10 min ischemia (uptake ratio was 4.46±3.16 and 2.02±0.47, respectively), whereas, no 
significant uptake was observed in 5 min ischemia at 30 min after reperfusion. 99mTc-annexin 
V uptake in 15 min and 10 min ischemia reduced at 90 min (uptake ratio was 3.49±1.78 and 
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1.47±0.11, respectively) and only mild uptake was observed at 6 h and 24 h after reperfusion. 
Interestingly, no morphological sign of necrosis and apoptosis was observed until 24 h after 
reperfusion in 10 min ischemia and only micro foci of cell degeneration and cell infiltration 
were observed until 24 h after reperfusion in 15 min ischemia, with mild TUNEL positivity 
which peaked at 6 hr (1.03±0.40% in 10 min ischemia and 2.84±0.94% in 15 min ischemia). 
These data indicate that 99mTc-annexin V uptake can be observed after mild ischemic insults 
those do not result in myocardial infarction. 
Several cardioprotective interventions such as ischemic preconditioning, postconditioning, 
and caspase inhibitor preparation attenuate 99mTc-annexin V uptake (Taki, et al., 2007). 
Ischemic preconditioning suppressed 99mTc-annexin V binding by 90 % of control and 
postoconditioning and caspase inhibitor attenuate the binding by around 70 %. 
Reversibility of PS externalization in brief ischemia was demonstrated (Kenis, et al., 2010). In 
murine myocardium with 5 min ischemia and 90 min and 6 h of reperfusion, fluorescent 
labeled annexin V injected before 10 min of sacrifice binds cell surface, but not at 24 h after 
reperfusion. On the other hand fluorescent-annexin V injected at the onset of reperfusion 
exclusively localized intracellularly at 90 min, 6 h, and 24h after reperfusion. No TUNEL 
positivity was observed in this 5 min ischemia and reperfusion model. These data indicate 
that in brief ischemia, PS externalizes transiently, which is amenable to targeting by annexin 
V for at least 6 h after reperfusion, and internalize after annexin V binding (reversibility of 
the apoptotic process). 
3.3 Clinical findings and potential future application 
In human pathological study by TUNEL staining and DNA electrophoresis, widespread 
apoptosis in infarcts was observed only a few hours in age before the appearance of 
coagulative necrosis (Veinot, et al. 1997). In addition, TUNEL positibity was observed 
primarily in myocytes containing contraction bands, which occur predominantly in regions 
of reperfused myocardium. These findings are consistent with animal experiment, and in 
infarcted human myocardium, apoptosis is the early and predominant form of cell death 
and its appearance is accelerated in reperfused myocardium. 
First clinical imaging with 99mTc-annexin V in 7 patients with acute myocardial infarction 
demonstrated significant uptake of 99mTc-annexin V (injected 2 h after reperfusion) in the 
area corresponding to the perfusion defect in 6 patients (Hofstra, et al., 2000). Subsequent 
study in 9 patients with acute myocardial infarction, 99mTc-annexin V uptake (injected within 
1.5 - 7 h after reperfusion) was again clearly visualized on SPECT performed at 15 h later in 
infracted areas with a matching perfusion defect confirmed by 99mTc-sestamibi SPECT 
before reperfusion. Repeat 99mTc-sestamibi SPECT at 1 – 3 week after the onset of infarction 
demonstrated that the perfusion defects were significantly smaller than the defects in acute 
phase, suggesting that the significant amount of myocardium in perfusion defect with 99mTc-
annexin V uptake in acute phase might be in reversible damage rather than irreversible 
necrosis. Imaging of the extent of apoptosis resulting from acute coronary syndromes could 
be a valuable tool to help guide revascularization strategies and therapy with anti-apoptotic 
drugs if available in near future. Other potential application of 99mTc-annexin V imaging 
would be in the detection of myocardial ischemic insults in patients with acute coronary 
syndrome without ST elevation and troponin leakage, in assessment of the effect of 
revascularization in acute coronary syndrome, in evaluation of the effect of postconditioning 
at reperfusion therapy, in detection of transient PS exetrnalization due to brief spontaneous 
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or stress induced ischemia. However, several questions yet to be answered concerning the 
clinical application of 99mTc-annexin V imaging. In vivo imaging 1 hr after tracer injection is 
feasible in rats because blood clearance of 99mTc-annexin V was rather fast, although, the 
earliest optimal time for imaging after tracer injection should be investigate in human. In 
heart transplantation patients, it was revealed that 99mTc-annexin V SPECT imgaing was 
possible 1 h after tracer injection (Narula, et al., 2001). Speedy imaging after tracer injection 
is crucial especially in emergency situation. Are therapeutic interventions beneficial for all 
annexin-positive myocardium, or in only specific pathological status, or in only limited time 
window? How much of the shift from necrosis to apoptosis by therapeutic intervention is 
cardioprotective (Narula, et al., 2003)? Necrosis is more harmful than apoptosis, because 
cells are removed without inflammation in apoptosis but cells are removed with 
inflammation and fibrosis follows in necrosis. Is annexin V positive scan in stress induced 
ischemia related to subsequent prognosis, or indication of PCI? These potential imaging 
concepts of the assessment of myocardial injury, stress, cell death in acute ischemia should 
be validated in clinical studies. 
It has been increasingly clear that apoptosis is a major contributor to early cardiomyocyte 
cell death after acute myocardial infarction, and is involved in post myocardial infarction 
ventricular dysfunction and adverse remodeling that develop heart failure. These findings 
emphasize the need for the reliable in-vivo imaging of apoptosis that assess the ongoing 
pathology so that rational preventive therapies can be applied and to assess the consequence 
of therapies. 99mTc-annexin V imaging might be applied to assess myocardium at risk or cell 
death in acute coronary syndrome and prediction of the ventricular remodeling after 
myocardial infarction and heart failure by allowing visualization of ongoing PS 
externalization that might precede or underlie change in pathophysiology, morphology, and 
LV dysfunction. 
4. Apoptosis imaging in heart failure and cardiomyopathy 
In spite of dramatic improvement of therapies in acute coronary syndrome, post acute 
myocardial infarction mortality has reached a plateau and post infarction heart failure due 
to ventricular remodeling is on the increase. About 15 to 25 % of acute myocardial infarction 
patients develop heart failure that remains a progressive despite of continuous 
pharmacological therapy. It has been reported that myocardial apoptosis shortly after acute 
myocardial infarction might be a strong predictor of unfavorable LV remodeling and early 
post infarction symptomatic heart failure in 16 patients dying ≥10 days after myocardial 
infarction (Abbate, et al., 2003). 
In rats with anterior myocardial infarction, 28-day infusion of caspase inhibitor after 
infarction ameliorated apoptosis, preserved myocardial contractile proteins, decreased 
myocardial interstitial collagen deposite, reduced systolic dysfunction, and attenuated LV 
remodeling (Chandrashekhar, et al., 2004). If so, apoptosis imaging could be a promising 
noninvasive method to identify patients at risk of heart failure development due to LV 
remodeling and to monitor the treatment effect if some specific anti-apoptotic agents will 
reach the stage of clinical study.  
In patients with advanced heart failure, low but abnormal rate of cardiac myocyte apoptosis 
persist for months (0.08% to 0.25% in heart failure vs 0.001% to 0.002% in normal subjects), 
thereby ultimately might result in a large loss of functional cardimyocytes (Olivetti, et al.,  
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1997; Saraste, et al., 1999; Guerra, et al., 1999). In study with transgenic mice that express a 
conditionally active caspase exclusively in the myocardium, low rate of cardiomyocyte 
apoptosis as 0.023% is sufficient to cause a lethal dilated cardiomyopathy. Conversely, 
inhibition of cardiac myocyte apoptosis by caspase inhibitor in this murine model largely 
prevents the development of cardiac dilation and contractile dysfunction, indicating that 
myocyte apoptosis may be a causal mechanism of heart failure, and inhibition of this cell 
death process may constitute the basis for novel therapies (Wencker, et al., 2003). The low 
level of cell death due to apoptosis in heart failure makes detection of apoptosis with the 
current techniques very challenging.  
In recent study in 9 consecutive patients with advanced nonischemic cardiomyopathy (8 
dilated and 1 hypertrophic cardiomyopathy) and 2 relatives, 5 patients showed focal or 
global 99mTc-annexin V uptake in the left ventricular myocardium. Interestingly, these 5 
patients with  99mTc-annexin V uptake had experienced a significant worsening or a recent 
onset of heart failure, on the contrary, 4 patients without 99mTc-annexin V uptake had no 
recent evidence of worsening of heart failure. In addition, during a follow up of 1 year, 4 
patients with 99mTc-annexin V uptake showed a decline of LVEF, on the other hand, in 
patients without 99mTc-annexin V uptake, clinical status and LVEF remained stable 
(Kietselaer, et al., 2007). These data indicate that the 99mTc-annexin V imaging in advanced 
non-ischemic cardiomyopathy, may identify the patients with high risk who might benefite 
from cell death blocking therapies. 
5. Apoptosis imaging in myocarditis 
In a rat model of autoimmune myocarditis, 99mTc-annexin V (HYNIC annexin V) and 14C-
deoxyglucose (DG) uptakes were examined (Tokita, et al.,2003). Myocarditis was triggered 
by an immunization of rats by infusing porcine cardiac myosine and the rats formed 
antibodies against the myosin and developed myocarditis. In acute phase of myocarditis, 
both 99mTc-annexin V (2.8 time more than normal rats) and 14C-DG (2.7 time more than 
normal rats) uptake increased significantly, however, only 99mTc-annexin V distribution 
correlated with the TUNEL positive area, and the distribution of 14C-DG correlated with 
inflammatory cell infiltration. In subacute phase, 99mTc-annexin V uptake returned normal 
level, on the other hand, 14C-DG uptake decreased but still higher uptake reflecting 
prolonged mild inflammatory cell infiltration. In this model of immune myocarditis, there 
was a marked difference in distribution of apoptotic cell death and inflammation. The data 
indicates that 99mTc-annexin V uptake is specific in myocardial apoptotic process induced by 
inflammation and is independent of inflammatory cell infiltration. 
Another animal experiment in a rat model that develops spontaneous myocarditis 
mimicking catecholamine induced subacute myocarditis demonstrated significantly 
increased 99mTc-annexin V uptake in planar scinitgraphy. Autoradiogrpahy confirmed 
increased 99mTc-annexin V uptake. Histopatology demonstrated patchy areas of interstitial 
edema with inflammatory cells in the perivascular areas and at cardiocyte layers, and 
myocyte necrosis with nuclear extrusion, scattered throughout the myocardium and 
apostatin-positive cells were diffusely but inhomogeneously distributed throughout the 
myocardium (Peker, et al., 2004).  
In myocarditis, apoptosis imaging might play an important role, in confirming the diagnosis 
in terms of the extent of the involvement and disease activity, selecting patients with 
antiapoptotic therapy and monitoring the effect of therapy. 
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6. Apoptosis imaging in cardiotoxicity induced by chemotherapy  
The development of chemotherapy has played a significant role in the management of 
cancer patients. Of the classic cytotoxic agents, antracyclines are the still one of the most 
important agents for cancer therapy and are well known for their dose dependent acute and 
chronic cardiotoxicity, resulting in irreversible and progressive cardiac dysfunction and 
heart failure. Although new anticancer molecular targeting agents improved the prognosis 
of cancer patients, some agents may have serious cardiovascular side effect. Standard 
clinical approaches utilize the serial monitoring of the left ventricular ejection fraction to 
identify chemotherapy induced cardiotoxicity. For this purpose, radionuclide ECG gated 
blood-pool scintigraphy has been used as a gold standard technique. However, ejection 
fraction impairment is relatively late manifestation of myocardial damage. Therefore, the 
development of more sensitive methods is required to identify the cardiotoxicity before the 
onset of ventricular dysfunction.  
In a rat model of doxorubicin cardiotoxicity (cumulative dose: 7.5mg/Kg, 10mg/Kg, 
12.5mg/Kg), planar scintigraphy detected the increase of 99mTc-annexin V uptake dose 
dependently and correlated with expression of left ventricular atrial natriuretic factor 
messenger RNA (Bennink, et al., 2004). Another study with doxorubicin treated rats 
(cumulative dose: 7.5mg/Kg and 15mg/Kg) demonstrated that dose dependent increase in 
99mTc-annexin V uptake by SPECT/CT and TUNEL positivity. In contrast in this syudy, 
echocardiography detected ventricular dysfunction only at the highest doxorubicin dose 
( Gabrielson, et al., 2008). These data suggest that apoptosis imaging could serve as a more 
sensitive early marker of doxorubicin cardiotoxixity than left ventricular dysfunction, might 
providing the opportunity to modify or stop the chemotherapy before clinically overt heart 
failure. 
7. Apoptosis imaging heart transplantation 
Acute rejection remains a limiting factor of cardiac transplantation. The histopathologic 
manifestation of transplant rejection comprises perivascular and interstitial mononuclear 
inflammatory cell infiltration associated with myocyte apoptosis and necrosis. To monitor 
the acute rejection, endomyocardial biopsies are required frequently. Current guidelines 
recommend 15-20 endomyocardial biopsies in the first year after transplantation to monitor 
potential allograft rejection. However, invasive endomyocardial biopsy may be associated 
with a small risk of complications. If non-invasive imaging for the detection of transplant 
rejection is feasible, endomyocardial biopsies might be reduced.  
Study with rat model of allograft rejection demonstrated that significant 99mTc-annexin V 
uptake correlated well with the histologic grade of rejection and scattered positive TUNEL 
stainings were observed in graft-infiltrating inflammatory cells, endothelial cells, and 
myocytes. In addition, after the treatment of rejection with cyclosporine, no TUNEL 
positivity was observed and 99mTc-annexin V uptake decreased to baseline (Vriens, et al., 
1998). In 18 patients with cardiac allograft recipients, 5 had positive myocardial uptake of 
99mTc-annexin V at 1 h after the tracer injection and all these 5 patients showed at least 
moderate transplant rejection and caspase-3 staining in their biopsy specimens. On the other 
hand, 11 of 13 patients with no cardiac uptake of 99mTc-annexin V demonstrated no finding 
of rejection and other 2 patients showed only focal lymphomononuclear cell infiltration 
(Narula, et al., 2001).  In another clinical study with 10 patients with cardiac transplant, 2 
www.intechopen.com
 
Apoptosis Imaging in Diseased Myocardium 
 
261 
patients with moderate acute rejection by endomyocardial biopsy showed significant 99mTc-
annexin V uptake, however, specificity was suboptimal with 4 of 8 patients without rejection 
demonstrating significant 99mTc-annexin V uptake.  
All these animal and clinical studies revealed that the apoptosis imaging has potential to 
noninvasively identify patients with transplant rejection and monitor the response to 
immune modulation therapy. 
8. Conclusions 
For the imaging apoptosis, for the time being, it appears that agents that bind to markers 
expressing cell surface of apoptotic cells, such as annexin V and its derivatives, have 
advantage in terms of the sensitivity and specificity over other tracers. Based on the research 
achievement to date including experiences with 99mTc-annexin V imaging in patients, 99mTc-
annexin V and its related tracers are considered as one of the most suitable tracers for 
clinical application at this stage, and also the positron labeled tracers such as 18F-annexin V 
are desired to apply clinical imaging. In cardiac diseases that involve cardiomyocytes, 
myocytes loss implies loss of cardiac function because cardiomyctes cannot be regenerated 
through cell division. In acute coronary syndrome, measurement of cardiac biomarkers are 
standard diagnostic tool, but they reflect the results of cardiomyocytes death. Whereas, 
apoptosis imaging such as 99mTc-annexin V can identify the cells starting or undergoing 
apoptosis, however, part of PS exposure of these cells might be reversible and some cells are 
capable of surviving. Therefore, apoptosis imaging might be beneficial for future strategy of 
the patient’s management. Other than acute coronary syndrome, including heart failure, 
myocarditis, cardiomyopathies, and transplanted rejection, apoptotic cell death has turned 
out one of the crucial players in underlying pathophysiologies. Hence, apoptosis imaging in 
patients with various cardiac diseases will enhance the understanding of the ongoing 
pathophysiology, identification of high risk patients, and lead to effective therapies to 
salvage the myocardium in risk and be helpful in monitoring the effect of therapy. 
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